CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
CMVpp65-A*0201 peptide vaccine +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02396134
NCT02396134Phase 2Completed
CompareCT.gov

A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant

City of Hope Medical Center·interventional·Posted Mar 24, 2015·Updated Mar 3, 2025

In Brief

A Phase 2 clinical trial evaluating CMVpp65-A*0201 peptide vaccine, Placebo, and 1 other intervention for Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 13 related conditions. Completed, enrolled 61 participants across 5 sites.

Detailed Summary

This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant. Vaccines made from a peptide may help the body build an effective immune response and may reduce cytomegalovirus events after donor stem cell transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma, Adult Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, HLA-A*0201 Positive Cells Present, Myelodysplastic Syndrome, Adult Lymphoblastic Lymphoma, Chronic Lymphocytic Leukemia, Myelofibrosis, Myeloproliferative Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 24, 2015
Enrollment StartMay 21, 2015
Primary CompletionMar 4, 2018
Study CompletionSep 19, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.3 years ago

Interventions

CMVpp65-A*0201 peptide vaccinebiological

Given SC

Placeboother

Given SC

Laboratory Biomarker Analysisother

Correlative studies